Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-03-31

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project aims to establish whether an adapted extraction device is tolerable and will be able to measure chemical signals in baby's ISF. Insight into the chemical profiles found in the skin interstitial fluid (ISF) of healthy and diseased babies will identify signals that can be used to investigate the causes of eczema and propose new preventative strategies and effective treatments.

Specifically, it aims to:

1. Demonstrate that the developed ISF device can be used to extract biomarkers from the skin of babies non-invasively and is tolerable (not causing significant discomfort, bruising, or blister formation).
2. Compare the profile of chemical markers present in the ISF of healthy babies with babies that have developed eczema.
3. Compare the biomarker levels extracted from babies with eczema in lesional and non-lesional skin using the developed ISF device.
4. Compare the microbiome and metabolome profiles from swabs taken from babies with healthy skin and with eczema in lesional and non-lesional skin (exploratory outcome).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Efficacy and Safety of Enhanced External Counter-pulsation on Patients With Atopic Dermatitis and Inflammatory Skin Disease Requiring Wet Wrap Therapy

NCT06448702

Atopic Dermatitis Inflammatory Skin Disease

NOT_YET_RECRUITING NA

A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants

NCT06934980

Atopic Dermatitis Healthy Volunteers

COMPLETED

Skin Pathology Assessment With Optical Technologies

NCT04295824

Atopic Dermatitis Eczema

COMPLETED

Characterization of Chronic Hand Eczema

NCT05026554

Chronic Hand Eczema Atopic Dermatitis

RECRUITING

Erythema Toxicum Neonatorum in Newborns and the Development of Asthma

NCT00178152

Asthma Erythema Toxicum Neonatorum

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eczema is a skin condition that affects up to 20% of children worldwide, and its numbers are increasing. Our goal is to learn more about eczema by studying how immune signals in the skin differ between babies with eczema and those with healthy skin. To do this, investigators will gently use a non-invasive device to extract a tiny amount of fluid from the top layer of baby's skin(Interstitial Skin Fluid). By studying these samples, investigators want to compare the immune signals of healthy skin and skin affected by eczema. This research aims to deepen our understanding of why eczema causes inflammation and to identify the specific signals involved in this process, particularly in babies.

A total of 30 babies will be recruited, of which 15 will be healthy and 15 have eczema. They will be invited to attend for one visit lasting 1-1.5 hours. During the study visit, clinical information such as demographics, medical history and co-morbidities as well as eczema treatments (where applicable) and other skin care practices will be collected. For babies that have eczema, an eczema area and severity index (EASI) assessment will be conducted. For all participants enrolled onto the study, Interstitial Skin Fluid (ISF) samples will be extracted from the skin using a painless, non-invasive device that is well-tolerated and will not cause any pain or skin damage to the baby. Samples for assessing the skin microbiome will be collected, including skin swabs and tape strips taken in a pain-free manner. Skin barrier function assessments such as Transepidermal water loss (TEWL) will also be performed helping us understand how well the baby's skin holds onto moisture. This is a painless and non-invasive device that doesn't cause any discomfort to the baby.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eczema Atopic Dermatitis Atopic Eczema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy babies

Babies up to 6 months old without eczema

No interventions assigned to this group

Babies with Eczema

Babies up to 6 months old with eczema

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy babies and babies with atopic dermatitis up to 6 months old.
2. Ability of parents/guardians/caregivers to provide written informed consent for study participation.
3. Willingness of parents/guardians/caregivers to comply with all study requirements.
4. Parents/guardians/caregivers competent use of English language.

Exclusion Criteria

1. Parents/guardians/caregivers unable to give informed consent.
2. Preterm birth (defined as birth before 37 completed weeks gestation).
3. Significant inflammatory skin disease at birth.
4. Baby has any other serious health issue.

Minimum Eligible Age

0 Months

Maximum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes